194 related articles for article (PubMed ID: 32057576)
1. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
Samy N; Reichhardt D; Schmidt D; Chen LM; Silbernagl G; Vidojkovic S; Meyer TP; Jordan E; Adams T; Weidenthaler H; Stroukova D; De Carli S; Chaplin P
Vaccine; 2020 Mar; 38(11):2608-2619. PubMed ID: 32057576
[TBL] [Abstract][Full Text] [Related]
2. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
Green CA; Scarselli E; Voysey M; Capone S; Vitelli A; Nicosia A; Cortese R; Thompson AJ; Sande CS; de Lara C; Klenerman P; Pollard AJ
BMJ Open; 2015 Oct; 5(10):e008748. PubMed ID: 26510727
[TBL] [Abstract][Full Text] [Related]
4. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
[TBL] [Abstract][Full Text] [Related]
5. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.
Jordan E; Kabir G; Schultz S; Silbernagl G; Schmidt D; Jenkins VA; Weidenthaler H; Stroukova D; Martin BK; De Moerlooze L
J Infect Dis; 2023 Oct; 228(8):999-1011. PubMed ID: 37079393
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
[TBL] [Abstract][Full Text] [Related]
7. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
Jordan E; Lawrence SJ; Meyer TPH; Schmidt D; Schultz S; Mueller J; Stroukova D; Koenen B; Gruenert R; Silbernagl G; Vidojkovic S; Chen LM; Weidenthaler H; Samy N; Chaplin P
J Infect Dis; 2021 Mar; 223(6):1062-1072. PubMed ID: 32726422
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
Eto T; Okubo Y; Momose A; Tamura H; Zheng R; Callendret B; Bastian AR; Comeaux CA
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13336. PubMed ID: 38880785
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
12. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial.
Sáez-Llorens X; Norero X; Mussi-Pinhata MM; Luciani K; de la Cueva IS; Díez-Domingo J; Lopez-Medina E; Epalza C; Brzostek J; Szymański H; Boucher FD; Cetin BS; De Leon T; Dinleyici EC; Gabriel MÁM; Ince T; Macias-Parra M; Langley JM; Martinón-Torres F; Rämet M; Kuchar E; Pinto J; Puthanakit T; Baquero-Artigao F; Gattinara GC; Arribas JMM; Ramos Amador JT; Szenborn L; Tapiero B; Anderson EJ; Campbell JD; Faust SN; Nikic V; Zhou Y; Pu W; Friel D; Dieussaert I; Lopez AG; McPhee R; Stoszek SK; Vanhoutte N
J Infect Dis; 2024 Jan; 229(1):95-107. PubMed ID: 37477875
[TBL] [Abstract][Full Text] [Related]
18. Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.
Russell MS; Thulasi Raman SN; Gravel C; Zhang W; Pfeifle A; Chen W; Van Domselaar G; Safronetz D; Johnston M; Sauve S; Wang L; Rosu-Myles M; Cao J; Li X
Front Immunol; 2021; 12():747866. PubMed ID: 34603336
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
Fierro C; Weidenthaler H; Vidojkovic S; Schmidt D; Gafoor Z; Stroukova D; Zwiers S; Müller J; Volkmann A
Vaccine; 2024 Apr; 42(10):2695-2706. PubMed ID: 38494412
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
